October 8, 2018 / 5:22 AM / 10 days ago

BRIEF-Novartis seeks U.S., EU regulatory approval for MS drug Siponimod

Oct 8 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES FDA AND EMA FILING ACCEPTANCE OF SIPONIMOD, THE FIRST AND ONLY DRUG SHOWN TO MEANINGFULLY DELAY DISABILITY PROGRESSION IN TYPICAL SPMS PATIENTS

* SAYS REGULATORY ACTION FOR SIPONIMOD IS ANTICIPATED IN US IN MARCH OF 2019 AND IN EUROPE IN LATE 2019 Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below